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Abstract
Background: Programmed cell death or apoptosis is an essential process for tissue homeostasis. Hepatocyte
apoptosis is a common mechanism to many forms of liver disease. This study was undertaken to test the role of
ILK in hepatocyte survival and response to injury using a Jo-2-induced apoptosis model.
Methods: For survival experiments, ILK KO and WT mice received a single intraperitoneal injection of the agonistic
anti-Fas monoclonal antibody Jo-2 at the lethal dose (0.4 μg/g body weight) or sublethal dose (0.16 μg/g body
weight). For further mechanistic studies sublethal dose of Fas monoclonal antibody was chosen.
Results: There was 100% mortality in the WT mice as compared to 50% in the KO mice. We also found that
hepatocyte specific ILK KO mice (integrin linked kinase) died much later than WT mice after challenge with a lethal
dose of Fas agonist Jo-2. At sublethal dose of Jo-2, there was 20% mortality in KO mice with minimal apoptosis
whereas WT mice developed extensive apoptosis and liver injury leading to 70% mortality due to liver failure at
12 h. Proteins known to be associated with cell survival/death were differentially expressed in the 2 groups. In ILK
KO mice there was downregulation of proapoptotic genes and upregulation of antiapoptotic genes.
Conclusions: Mechanistic insights revealed that pro-survival pathways such as Akt, ERK1/2, and NFkB signaling
were upregulated in the ILK KO mice. Inhibition of only NFkB and ERK1/2 signaling led to an increase in the
susceptibility of ILK KO hepatocytes to Jo-2-induced apoptosis. These studies suggest that ILK elimination from
hepatocytes protects against Jo-2 induced apoptosis by upregulating survival pathways. FAK decrease may also
play a role in this process. The results presented show that the signaling effects of ILK related to these functions
are mediated in part mediated through NFkB and ERK1/2 signaling.
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Background
Programmed cell death or apoptosis is an essential process
for tissue homeostasis. Hepatocyte apoptosis is a common
mechanism to many forms of liver disease. It has been
recognized to contribute to the pathogenesis of alcoholic
liver disease, nonalcoholic steatohepatitis, viral hepatitis,
cholestatic liver disease, and ischemia/reperfusion injury
[1-4]. Apoptosis can be triggered by Fas receptor mediated
signaling as well as different stimuli that provoke cell
stress. All these stimuli converge at the activation of cas-
pase 3 that leads to internucleosomal DNA degradation,
chromatin condensation, cell shrinkage, and formation of
small apoptotic bodies that are phagocytosed by neighbor-
ing macrophages [4]. The liver is very sensitive to Fas-
induced apoptosis. Administration anti-Fas agonistic anti-
body Jo-2 to mice leads to rapid death of the animals due
to fulminant hepatitis, mimicking certain forms of acute
liver failure (ALF) in humans [5]. Fas (CD95/APO-1), a
43-kDa cell surface glycoprotein, belongs to the tumor
necrosis factor receptor superfamily, and mediates apopto-
sis upon binding with its cognate ligand, or artificially with
specific agonistic antibodies.
Communication between cells and the extracellular
matrix (ECM) is achieved through integrins and the asso-
ciated integrin proximal adhesion molecules. Through
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these molecules transmit signals from the ECM to the
interior of the cell and regulate many fundamental cellular
processes. Integrin-linked kinase (ILK) is a b1- and b3-
integrin-interacting cell matrix adhesion protein that has
been shown to be crucial for a number of cellular pro-
cesses such as survival, differentiation, proliferation,
migration, and angiogenesis [6-8]. Previous studies in our
lab have shown that acute elimination of ILK by injection
of adenovirus expressing Cre recombinase in the tail vein
of ILKflox/flox mice led to massive hepatocyte apoptosis
[9]. Genetic ablation of ILK also results in some degree of
apoptosis [10] but also to an enhancement of hepatocyte
proliferation, suggesting that ILK might be playing a role
in hepatocyte survival. This study was undertaken to test
the role of ILK in hepatocyte survival and response to
injury using a Jo-2-induced apoptosis model. Here we
report that genetic ablation of ILK from hepatocytes pro-
tects from Jo-2 induced apoptosis due to upregulation of
survival signaling mainly ERK and NFBs i g n a l i n g .
Methods
Generation of liver specific ILK/liver-/- mice
ILK floxed animals were generated as described previously
[10] and donated by Drs. René St. Arnaud (Shriners Hos-
pital and McGill University, Montréal) and Shoukat Deod-
har (British Columbia Cancer Agency and Vancouver
Hospital, Jack Bell Research Center, Vancouver), and
mated with AFP-enhancer-albumin-promoter-Cre-recom-
binase-expressing mice which were kindly provided by Dr.
Klaus Kaestner (University of Pennsylvania). The off-
spring were genotyped as described previously [11] and
the ILK-floxed/floxed Cre-positive mice were considered
to be ILK-knockout (ILK KO), while their Cre-negative
siblings were used as controls. All animals were housed in
the animal facility of the University of Pittsburgh in accor-
dance with the guidelines of the Institutional Animal Use
and Care Committee of the University of Pittsburgh.
Induction of apoptosis
For survival experiments, male 30 week-old ILK KO (n =
10) and control mice (n = 10) received a single intraperito-
neal injection of the agonistic anti-Fas monoclonal anti-
body Jo-2 (BD Pharmingen, San Diego, CA) at the lethal
dose (0.4 μg/g body weight) or sublethal dose (0.16 μg/g
body weight) diluted in sterile saline. The mice were moni-
tored for up to 24 hours, and the time of death was
recorded. The Fas injury model was induced in controls
and ILK KO mice with a single intraperitoneal injection of
Jo-2 at the dose of 0.16 μg/g weight. At the indicated time
points (up to 12 hours) after Jo-2 injection, mice were
sacrificed. Livers were snap frozen in liquid nitrogen or
formalin-fixed and paraffin embedded for histopathologi-
cal studies. All procedures performed on these mice were
approved under the IACUC protocol and conducted
according to National Institute of Health guidelines.
Isolation, culture and treatment of mouse hepatocytes
Hepatocytes were isolated from male ILK KO and control
mice as described previously [10]. Cells were plated onto
collagen-coated 6-well dishes (type I collagen, Collaborative
Biomedical, Bedford, MA) 5 × 10
5 cells per well. Cultures
were maintained in minimal essential medium supplemen-
ted with 10% fetal calf serum, nonessential amino acids,
2 mM glutamine, and antibiotics (all from Invitrogen).
After 2-h incubation medium was removed, and cells were
refed the same medium with 0.5% fetal calf serum and
incubated overnight. Apoptosis was induced in cultured
mouse hepatocytes by treatment with 0.5 μg/ml anti-Fas
antibody and 0.05 μg/ml actinomycin D as described
before [12]. The effect of ILK deletion on Fas-mediated
apoptosis was also tested in the presence of the extracellu-
lar-regulated kinase 1/2 inhibitor U0126 (20 μM, Cell Sig-
naling), the phosphatidylinositol 3-kinase (PI3K) inhibitor
LY-294002 (50 μM, Cell signaling) and NFBp e p t i d e
(30 μM, Calbiochem). Doses of the inhibitors and peptides
were selected based on previous studies with isolated hepa-
tocytes [13].
Measurement of apoptosis
Apoptotic nuclei were detected by terminal deoxynu-
cleotidyl transferase-mediated deoxyuridine triphosphate
nick-end labeling staining using the ApopTag Peroxi-
dase kit (Millipore, Billerica, MA). Activation of caspase
3/7 in cell lysates was detected using a commercially
available kit (Promega, Madison, WI).
Western blot analysis
Liver Homogenates were prepared as described pre-
viously [10]. The following primary antibodies were
used in this study: rabbit anti-cleaved caspase 3, Rabbit
anti-BAD and phospho BAD, Rabbit anti-Bcl-2, Rabbit
anti-Bcl-xl, Rabbit anti phospho Akt (serine 473), Rabbit
anti phospho ERK (Thr202/Tyr204), Rabbit cleaved
PARP, Rabbit p65 (Cell Signaling Technologies, Dan-
vers, MA), Mouse anti Fas (Santa Cruz) and mouse
anti-b-actin (Chemicon, Temecula, CA). Donkey anti-
rabbit and anti-mouse secondary antibodies were pur-
chased from Jackson ImmunoResearch Laboratories
(West Grove, PA) and were used at 1:50,000 dilutions.
Results
Effect of genetic ablation of ILK from hepatocytes on Fas-
induced animal death and fulminant hepatitis
To determine whether ILK may play a role in the regu-
lation of hepatocyte survival from apoptosis inducing
stimuli, we determined the sensitivity of mice lacking
ILK to Fas-induced apoptosis. We injected ILK KO and
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(0.4 μg/g) of Jo-2. There was 50% mortality in the ILK
KO (5/10) at 24 hours after Jo-2 injection, while all the
controls died much faster than the ILK KO mice, show-
ing 100% mortality (10/10) by 7 h after challenge
whereas ILK KO mice were still alive at this time point
(Figure 1A). Next we analyzed the effect of a sublethal
dose of Jo-2 antibody (0.16 μg/g) on the survival of ILK
KO and control mice. With this lower dose of Jo-2,
there was 20% mortality (2/10) in the ILK KO mice
while there was 70% mortality (7/10) in control mice by
24 h (Figure 1A). These data suggested that genetic
ablation of ILK from hepatocytes protected the mice
against Fas-induced apoptosis. We then evaluated the
degree of hepatocellular damage in ILK KO and control
mice in response to the sublethal dose of Jo-2. Histolo-
gical examination of liver samples obtained at 6 h after
sublethal dose of Jo-2 showed a higher degree of liver
injury and the presence of parenchymal hemorrhages in
control mice but not in ILK KO mice (Figure 1B). The
different response to Jo-2 observed in ILK KO and con-
trol mice could be attributable in part to reduced hepa-
tic expression of Fas receptor, because the basal levels
of Fas as determined by Western blotting was lower in
the livers of the ILK KO liver (Figure 1C). The expres-
sion was also lower in the hepatocytes isolated from ILK
KO mice compared to WT mice (Figure 1C). Thus, it is
likely that ILK regulates the expression of Fas receptor.
Similarly, TUNEL assay of the liver sections demon-
strated more abundant apoptotic nuclei in control mice
than in ILK KO mice. Activation of capase3/7 was also
higher in the control mice than ILK KO mice at 6 and
12 h after Jo-2 administration. In addition, expression of
cleaved caspase 3 and PARP were also higher in the
control than the ILK KO mice at both 6 and 12 h after
a sublethal dose of Jo-2 (Figure 2A, B and 2C).
Mechanism of protection of ILK KO mice against Jo-2
induced hepatic failure
We looked at the protein expression of various anti apop-
totic proteins involved in Fas-induced apoptosis. Bcl-2
family proteins inhibit apoptosis induced by variety of sti-
muli, including Fas mediated apoptosis [1,14,15]. We
assessed the expression of the antiapoptotic protein Bcl-
xL and Bcl-2 by Western blotting at 0, 6 and 12 h after
the injection of sublethal dose of anti-Fas antibody (Fig-
ure 2C). Bcl-xL and Bcl-2 proteins levels were decreased
in the liver of control mice treated with Jo2; however, in
ILK KO mice Bcl-xl and Bcl-2 protein levels were main-
tain in response to a sublethal dose of Jo-2 (Figure 2C).
The ILK KO mice also had higher expression of Bcl-2 at
basal levels (Figure 2C). We also looked at the protein
expression of Bcl-2-associated death promoter (BAD)
after Jo-2 administration. Dephosphorylated BAD forms
a heterodimer with Bcl-2 and Bcl-xl, inactivating them,
and thus allowing Fas-triggered apoptosis to take place.
BAD phosphorylation is thus anti-apoptotic, and BAD
dephosphorylation is pro-apoptotic [1]. In the control
mice the BAD levels did not change before and after Jo-2
administration but there was an induction of BAD after
Jo-2 administration in the ILK KO mice (Figure 2D). The
expression of p-BAD which is antiapoptotic was higher
Figure 1 Protection of ILK KO mice against Fas-induced liver injury and apoptosis. A) Kaplan Meier survival curves after a sublethal (0.16
μg/g) (left graph) and a lethal dose (0.40 μg/g) (right graph) of Jo-2. B) Hematoxylin-eosin staining of liver sections at 6 h after a sublethal
injection of Jo-2 shows reduced hemorrhage and apoptotic cell bodies in the ILK KO mice. Double arrow = 300 μm. C) Representative Western
blots of basal levels of Fas receptor in whole livers and hepatocytes isolated from WT and ILK KO mice.
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pared to the control mice. The basal level of p-BAD was
also higher in the ILK KO mice as compared to the con-
trols (Figure 2D). Expression of p-BAD in control was
barely detectable at basal levels (Figure 2D).
To understand the molecular events underlying the
resistance of ILK KO mice to Jo-2 induced apoptosis,
we examined the activation of several survival pathways
known to be involved in cytoprotection against Fas-
induced apoptosis. We investigated phosphorylation of
Akt, Erk1/2, and NFB activation which are known to
be involved in cytoprotection against Fas-induced apop-
tosis [1,12,16,17]. There was an induction of both total
and p-Akt after Jo-2 administration both in ILK KO and
control mice at 6 and 12 h after Jo-2 administration
(Figure 2E). The induction was more enhanced in the
ILK KO mice than the controls at 6 h after Jo-2 admin-
istration (Figure 2E). Basal level of p-Akt was also higher
in the ILK KO mice as compared to the controls. Levels
of p-Erk1/2 levels at 6 h decreased after Jo-2 administra-
tion in the controls while they remain stable in the ILK
KO mice (Figure 2E). Levels of total ERK were also
slightly lower in the WT than ILK KO. Also, levels of
the NFkB subunit p65 go down after Jo-2 in the control
mice at 6 h while they were upregulated in the ILK KO
mice. The basal level of p65 was also higher in the ILK
KO mice as compared to the controls (Figure 2E).
These studies suggest that the survival signaling machin-
ery is upregulated in the ILK KO as compared to the
controls before and after Jo-2 administration.
Phosphorylation of ERK1/2 and NFB activation are
primarily responsible for protecting ILK KO hepatocytes
from apoptosis
Consistent with our in vivo data, hepatocytes isolated
from ILK KO mice were resistant to Jo-2 and Actinomy-
cin D induced apoptosis (Figure 3A). Our in vivo data
suggest that increase in survival pathways like Akt,
Figure 2 Proteins associated with apoptosis and survival pathways are differentially expressed in the ILK KO mice. A) Tunnel assay 6 h
after a sublethal dose of Jo-2 showing increased number of apoptotic bodies in the WT mice as compared to the ILK KO mice. Double arrow =
300 μm. B) Caspase 3/7 activation after a sublethal dose of Jo-2. C) Expression of various apoptotic and antiapoptotic proteins after a sublethal
dose of Jo-2. D) Expression of BAD and p-BAD after a sublethal dose of Jo-2. E) Expression of various survival pathways after a sublethal dose of
Jo-2.
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tion. We used pharmacological inhibitors for Akt and
Erk1/2 and peptide inhibitor for NFB. Inhibition of
Erk1/2 and NFB led to increased susceptibility of ILK
KO hepatocytes to Jo-2 and Actinomycin D induced
apoptosis (Figure 3B and 3C). Pharmacological inhibitor
against ERK1/2 was effective in downregulating the
phosphorylation of ERK (Figure 3D). Inhibition of Akt
did not have any effect (Figure 3B). Thus, NFBa n d
Erk1/2 but not Akt seem to be involved in affording
protection to ILK KO hepatocytes to Jo-2 and actinomy-
cin D induced apoptosis.
Focal adhesion kinase signaling
Focal adhesion kinase is another enzyme associated with
integrin signaling [18,19]. We looked into the possibility
of FAK signaling compensating for the loss of ILK sig-
naling. Genetic removal of ILK led to lower expression
of FAK in the whole liver as well as hepatocytes isolated
from the ILK KO mice (0 h of Figure 3E and 3F). Acti-
vation of FAK as a result of tyrosine phosphorylation at
397 residue was also lower in the whole liver as well as
hepatocytes of the ILK KO mice (0 h of Figure 3E and
3F). Interestingly, administration of Jo-2 both in vivo
and in vitro resulted in an increase in total as well as
activated FAK in the ILK KO mice (Figure 3E and 3F).
The WT mice on the other hand showed downregula-
tion of total and activated FAK after Jo-2 administration
both in vivo and in vitro. Several studies have shown
the protective role of FAK in apoptosis [20-22]. Thus,
upregulation of FAK signaling in the ILK KO mice after
Jo-2 administration may also be playing an important
Figure 3 ILK KO hepatocytes are protected against Jo-2 induced apoptosis in vitro. A) Caspase 3/7 activity at 6 h after treatment of WT
and ILK KO hepatocytes with Jo-2 (0.5 μg/ml) and Actinomycin D (0.05 μg/ml). Fold change is the ratio of luminescence value of treatment
group with its corresponding no treatment group. B) Effect of ERK1/2 inhibition using a MEK inhibitor U0126 (20 μM). Representative Western
blots of cleaved caspase and PARP 6 h after Jo-2, vehicle or Jo-2+inhibitor administration. (Akt Inh: Akt inhibitor LY-294002, ERK Inh: ERK inhibitor
U0126) C) Representative Western blots showing inhibition of phosphorylation of ERK1/2 by U0126 in ILK KO hepatocytes after 6 h after
treatment with U0126. D) Representative Western blots of PARP after inhibition of NFB using a synthetic peptide 6 h after treatment with
Control peptide (CP), CP+Jo-2 and NP+Jo-2 (NFB peptide). (CP: control peptide, NP: NFB peptide). E) Total FAK and p-FAK at 0 and 6 h after
Jo-2 administration in vitro. F) Total FAK and p-FAK at 0 and 6 h after Jo-2 administration in vivo.
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ventional studies will provide a better understanding of
the role of FAK signaling in Jo-2 induced apoptosis in
absence of ILK signaling.
Discussion
In this study we show that ILK is plays a regulatory role in
Fas mediated apoptosis. We present evidence that hepato-
cyte specific ILK KO mice are resistant to Fas-induced
apoptosis both in vivo and in vitro. Furthermore we show
that apoptotic injury in the ILK KO mice is associated
with an increase in antiapoptotic genes like Bcl-xl and Bcl-
2. Investigation of the mechanism behind this protection
revealed reduced expression of the Fas receptor in the ILK
KO mice. However, the lower expression of Fas receptor
in the ILK KO mice is not the only mechanism that could
afford that much protection. Thus, we looked at the other
possibilities that might also contribute to this protection.
The survival program of ILK is well established and
includes primarily activation of PI3K/Akt, ERK1/2 and
NFB pathway [6,7,23-25]. In agreement to these studies
we found induction of PI3K/Akt, ERK1/2 and NFBn o t
only after Jo-2 administration but also at basal levels in the
ILK KO mice. We then used a well described in the litera-
ture in vitro system of studying hepatocyte apoptosis using
Jo-2 and Actinomycin D. Pharmacological inhibition of
ERK using U0126 and peptide inhibition of NFB pathway
led to increased susceptibility of ILK KO hepatocytes to
Jo-2 induced apoptosis in hepatocyte cultures, suggesting
that ERK and NFB pathways but were the signaling med-
iators for ILK in this process. Inhibition of Akt using PI3K
inhibitor LY-294002 did not affect the degree of apoptosis
in ILK KO hepatocytes. Together the data suggests that
reduced expression of FAS receptor in the ILK KO mice
along with persistent upregulation of survival signals like
ERK1/2 and NFB signaling is the mechanism behind pro-
tection of ILK KO mice against Jo-2 induced liver failure.
It should be noted that our results differ to previously
published literature where upregulation of ILK in mam-
mary epithelial cells protects against apoptosis [26]. It is
conceivable that ILK may be promoting apoptosis in the
liver while it has a completely opposite role in the mam-
mary glands. Also, genetic elimination of a protein results
in many adaptive changes in the organ. It is likely that
genetic removal of ILK from the liver results in adaptive
changes in the liver that make them resistant to apoptosis.
Liver and mammary gland tissues also have different life
cycles. Differentiation of liver tends to be stable through
life whereas mammary glands undergo dramatic changes
in their differentiation both due to hormonal cycles as well
as during pregnancy.
A relevant question is why genetic ablation of ILK led to
increased activation of these survival pathways? Our cur-
rent studies as well as those we recently published
[10,27-29] suggest that ILK mediated signaling plays a reg-
ulatory role the balance between proliferation and apopto-
sis in hepatocytes. Previous studies from our laboratory
have also shown that in situations in which mitogenic sig-
nals to hepatocytes via EGFR or MET are suppressed,
there is up-regulation of pro-apoptotic pathways and
down-regulation of anti-apoptotic pathways [30,31]. The
delicate balance between hepatocyte proliferation versus
apoptosis underlies pathways leading to liver regeneration
or liver failure. ILK has been shown to have many roles in
tumor development, with studies describing different
effects in different tumors based on tissue origin
[24,25,32,33]. The signaling pathways by which ILK affects
these phenomena were not clear. Our current studies with
hepatocyte cultures show that at least in hepatocytes, the
effects of ILK on hepatocyte survival are mediated via
NFkB and ERK signaling. These signaling pathways also
have well known effects on hepatocyte proliferation, and
ILK seems to play a suppressive role in that regard (ILK
KO hepatocytes have enhanced proliferation, [10,27].
Conclusions
Here we report that genetic ablation of ILK from hepato-
c y t e sp r o t e c t sf r o mJ o - 2i n d u c e da p o p t o s i sd u et ou p r e -
gulation of survival signaling mainly ERK, FAK and
NFB signaling. The findings of this work provide a
mechanistic interpretationo ft h eI L Kr o l ei nt h e s ep r o -
cesses and underscore the complex role of ILK and integ-
rin signaling in control of proliferation, survival or death
of hepatocytes.
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